Skip to main content
. 2024 Apr 15;16(4):e58334. doi: 10.7759/cureus.58334

Table 2. Pre-TAVR laboratories and echocardiography results stratified by STS risk score.

Continuous variables are presented by median (IQR); categorical variables are presented by count (%).

TAVR: transcatheter aortic valve replacement; STS: Society of Thoracic Surgeons; LVEF: left ventricular ejection fraction; HFrEF: heart failure with reduced ejection fraction; AV: aortic valve; PPG: peak pressure gradient; MPG: mean pressure gradient, SPAP: systolic pulmonary artery pressure

*Mixed aortic valve disorder is defined as severe aortic stenosis with an aortic valve regurgitation grade of ≥3.

Variables Patients’ STS score
All (n=399) Low risk (n=200) Intermediate risk (n=136) High risk (n=63) P-value
Pre-procedural Laboratories
Hemoglobin (g/dL) 11.7 (10.4-12.9) 12.2 (11-13.3) 11.3 (10-12.5) 11 (9.7-11.8) <0.01
Creatinine (mg/dL) 1 (0.8-1.3) 1 (0.8-1.1) 1.1 (0.8-1.4) 1.2 (1-1.9) <0.01
Pre-procedural Echocardiography
LVEF % 60 (50-65) 60 (55-65) 60 (50-60) 60 (40-65) 0.377
HFrEF 84 (22) 36 (19.7) 27 (20) 21 (33.9) 0.051
Area (cm2) 0.75 (0.6-0.87) 0.75 (0.62-0.85) 0.78 (0.6-0.87) 0.75 (0.6-0.88) 0.96
AV PPG (mmHg) 70.5 (57-81.2) 71 (59-82.5) 71 (56-82) 64 (56-80) 0.348
AV MPG (mmHg) 44 (37-53) 45 (40-54) 44 (36-51) 40 (34.5-50) 0.08
SPAP (mmHg) 42 (37-53) 37 (30-50) 46 (36-58) 54 (42-68) <0.001
Mitral regurgitation ≥3 35 (9.6) 10 (5.6) 15 (11.5) 10 (16.9) 0.024
Tricuspid regurgitation ≥3 49 (14.2) 9 (5.6) 19 (15.1) 21 (36.8) <0.001
Aortic Valve Disease
Isolated AV stenosis 344 (87.3) 180 (91.8) 116 (85.9) 48 (76.2) 0.02
Isolated AV regurgitation 21 (5.3) 9 (4.6) 6 (4.4) 6 (9.5) 0.29
Mixed AV disease* 29 (7.4) 7 (3.6) 13 (9.6) 9 (14.3) 0.005
Aortic Valve Morphology
Tricuspid AV 355 (89) 181 (90.5) 120 (88.2) 54 (85.7) 0.54
Bicuspid AV 7 (1.8) 5 (2.5) 2 (1.5) 0 0.6
Bioprosthetic valve 32 (8) 11 (5.5) 13 (9.6) 8 (12.7) 0.13